Read Summary

Sacituzumab govitecan (Trodelvy) beat chemotherapy in patients with heavily pretreated endocrine resistant HR+/HER2- advanced breast cancer, who represent a ‘great clinical unmet need,’ says expert.
Medscape Medical News

Print Friendly, PDF & Email